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Summary Doctors who treat lung cancer in Ontario were previously asked how they would wish to be
managed if they developed non-small cell lung cancer and whether they would consent to participate in six
clinical trials for which they might be eligible. The proportion of these expert surrogate patients who would
consent to each clinical trial ranged from 11 to 64%. The results of this study were transmitted to the same
group of doctors who were asked to comment on the ethical acceptability of each trial in the light of this
information. The majority of physicians said that those trials to which less than 50% of expert surrogates
consented should not have been opened to patients. Sixty-nine per cent of doctors thought that new trials
should be evaluated in this way. We also present the results of a survey of 400 lay people in Ontario who
were asked to imagine that they had lung cancer and whether they would consent to participate in two of
these same clinical trials. Fifty per cent of lay people consented to a randomised trial of lobectomy versus
segmentectomy in early, operable disease (LCSC-821) compared to 64% of expert surrogates, and 48% of lay
people consented to a randomised trial of five different forms of chemotherapy in metastatic disease (SWOG-
8241) compared to 19% of doctors. It was concluded that the lay people were unable to discern differences in
the acceptability of clinical trials which were clear to experts in the field. Subsequently, respondents were told
about the decisions which doctors would make in the same circumstances and asked if this information would
modify their previous decisions. There is no net change in the proportion of patients consenting to the surgery
trial but the proportion of people consenting to the chemotherapy trial decreased by 40%. The majority of
lay people said that they would wish to have access to this type of information before consenting to
participate in a clinical trial.
Clinical research is necessary to progress in medicine and it
is, therefore, essential that we learn to integrate clinical trials
into routine practice. This is particularly true of oncology,
where only the systemic evaluation of new treatments
prevents the widespread use of unproven and often very
toxic therapies (Eisenhauer & Mackillop, 1988). When
doctors become researchers, however, patients become
potential research subjects and this alters the traditional
doctor-patient relationship. The clinician-investigator has a
dual role as physician in the service of today's patients and
scientist in the service of future generations, and with this
role comes a potential conflict of interest (Mackillop &
Johnston, 1986). The medical profession has recognised this
problem and has developed strategies designed to protect
both the patient and the doctor in this complex new
relationship. The most important of these is the doctrine of
'informed consent'.
The Nuremberg code (1949) stated that the voluntary
consent of the subject was absolutely essential in human
experimentation and the declaration of Helsinki (World
Medical Association, 1964) demanded that 'the potential
subject must be adequately informed of the aims, anticipated
benefits and potential hazards of the study and the
discomfort it may entail'. Hence 'informed consent' became
widely accepted as essential in clinical trials but has proved
difficult to define and, once defined, difficult to achieve in
practice.
Several empirical studies have shown that patients who
have given their 'informed consent' for treatment or
investigation may have little understanding of what they
have consented to (Epstein & Lasagna, 1969; Robinson &
Merav, 1976; Schultz et al., 1975; Muss et al., 1979). It has
been suggested that one of the barriers to communication is
the mental state of the patient with a major illness who may
be so emotionally disturbed as to preclude any rational
consideration of a proposed clinical trial (Fost, 1975).
Furthermore, medical information may not be of value to
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individuals who do not have the education or experience to
understand its significance (Ingelfinger, 1972). We have
recently shown that although cancer patients in Canada
today usually know their diagnosis, they are often unaware
of their prognosis and frequently overestimate the potential
benefit of treatment which they are receiving (Mackillop et
al., 1988b). Thus the patient's right to make the final
decision about participating in a clinical trial may be of
limited value and the medical profession must retain the
responsibility for ensuring that patients are not asked to
accept experimental treatments with unacceptably high risk/
benefit ratios.
We have developed an approach to this problem of
establishing what constitutes an ethically acceptable
experiment, based on the 'golden rule' that we should not do
anything to other people that we would not want them to do
to us. Our strategy is to get disinterested experts to ask
themselves if they would consent to participate in a trial if
they were in the patient's position. We recently asked
doctors who treat pulmonary neoplasms in Ontario to
imagine that they had lung cancer (four clinical situations
were described) and asked them if they would consent to
participate as patient-subjects in six different clinical trials
for which they might then have been eligible. The proportion
of doctors who would consent ranged from 64% for the
most acceptable trial to 11% for the least acceptable trial.
Reasons given for refusal varied, but many doctors felt that
certain trials offered unacceptable options for treatment. We
concluded that some patients with lung cancer currently
receive experimental therapies with high risk/benefit ratios
which experts in the field would not accept for themselves
(Mackillop et al., 1986).
We suggested that new clinical trials should be subjected
to evaluation by impartial experts using the surrogates
process. The opinions of expert surrogates might be useful to
the ethics committees or institutional review boards which
must decide what constitutes an ethically acceptable clinical
experiment. These data would only be of value, however, if
there was agreement among professionals and lay people
that the process was valid and produced meaningful results.
We have now resubmitted the results of our lung cancer
study to the 79 Ontario doctors who participated in the first
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survey to obtain their views on the relevance of these data
and to enlist their assistance in interpretation. We also
present the results of a survey of 400 lay people in Ontario
who were asked: (a) if they would be prepared to participate
in two of the cliiical trials which we had asked the doctors
about; (b) whether the opinions of expert surrogates would
influence their decisions; (c) whether they thought that the
opinions of expert surrogates should be used in evaluating
clinical trials before they were opened to patients; and (d)
how these data should be interpreted. We also describe how
a number of demographic factors influenced lay people's
decisions and how the construction of the questionnaire itself
influenced results.
Methods
Resurvey of doctors who treat lung cancer
Each doctor who responded to the original survey was sent a
summary of its results together with a second questionnaire
(copies of the instruments used in this study are available on
request) which asked:
1. Were the studies chosen, in your opinion, appropriately
representative of current trials in the four situations?
2. If the information now presented to you had been
available before you answered the original
questionnaire, would any of your responses about
preferred management, or willingness to participate in
trials, have changed? If so, in what way?
3. If the information now presented to you had been
available before these trials were opened to patients
should any of them have been stopped? If so, which?
4. Do you think it would be useful to submit new clinical
trials to expert surrogates in this way before they are
opened to patients?
Survey of lay people
The clinical scenarios. The two clinical situations and the
two clinical trials about which we asked the lay surrogates
were identical to those which had been used in our previous
expert surrogate survey (Mackillop et al., 1986). The two
trials chosen were LCSG-821, a randomised phase III study
of lobectomy versus wedge resection in early operable non-
small cell lung cancer, and SWOG-8241, a randomised phase
III study of five different forms of combination chemo-
therapy in metastatic non-small cell lung cancer. The
descriptions of the clinical situations were rewritten avoiding
medical terminology and expanded to include an explanation
of the nature of the illness, the forms of treatment available,
the therapeutic intent and the prognosis. The descriptions of
the clinical trials were expanded to include a description of
the purpose of each trial and the nature of randomisation.
The new draft descriptions of the situations were then
submitted to a group of oncologists who were asked to
ensure that the description of the clinical situation would be
comprehensible to the average patient and that the clinical
trials had been fairly described. A second draft incorporating
their suggestions was then submitted to a group of 15 lay
people from diverse backgrounds. They were asked to
complete the form as far as possible and to identify parts
which they did not understand or points where they would
have liked more information. Further corrections were made
and a final draft was then submitted to another group,
unconnected with the medical profession, who all found the
form comprehensible and were unable to make any further
constructive suggestions. The two scenarios are shown, in
their final form, in Appendices 1 and 2.
Description of doctors' attitudes to the clinical trials. The
opinions of doctors about these two clinical trials were
known from our previous study of the role of expert
surrogates in the evaluation of clinical trials (Mackillop et
al., 1986). In their complete form, the doctor's opinions were
described as shown in Appendices 3 and 4.
Questionnaire construction. The questionnaire in its final
form consisted of two sections. In section I respondents were
asked to imagine that they had been found to have lung
cancer. They were asked to consider the two clinical
situations in detail and to decide if they would be prepared
to consent to participate as patient-subjects in the two
clinical trials. They were asked to give reasons for their
decisions. When this section of the form had been
completed, the respondents opened a sealed envelope which
contained a description of the decisions which doctors
believed they would make in the same situations. In section
II of the questionnaire the respondents were then asked to
review their previous decision and to decide how they would
wish to act in the light of this new information. If they
changed their minds, they were asked to explain why and, if
not, they were asked to explain why not.
Variations in questionnaire structure. We wished to
determine whether the manner in which the doctors' decision
was presented influenced lay people's decisions and whether
the inclusion of the doctor's reasons for refusing to
participate would have an effect on lay people's decisions
independent of the simple proportion of doctors who would
consent. Thus, the section of the questionnaire presenting the
doctors' reasons finally had five different versions, each of
which was submitted to one-fifth of the sample population.
The first group received only a statement of the percentage
of doctors who would consent to participate (positive frame),
while the second group received only a statement of the
percentage of doctors who would not consent to participate
(negative frame). The third group received a statement of the
percentage of doctors who would consent and the percentage
of doctors who would not consent to participate (mixed
frame). The fourth group received a statement of the
percentage of doctors who would not consent to participate
and a summary of their reasons for refusing to participate
(negative frame and reasons), and the fifth group received a
statement of the proportion of doctors who would consent,
the percentage of doctors who would not consent and the
reasons given by those who refused to participate (mixed
frame and reasons). Doctors' reasons for consenting were
not elicited in the previous study and could not, therefore,
be included in this section.
Information about the population surveyed. The question-
naire included a section requesting the following basic
information about the subject: age, sex, country of birth,
marital status, occupation, educational level and smoking
status. We also determined whether the subject had ever had
cancer or any other major illness. Each subject was asked
about personal experience of cancer and of the various forms
of cancer treatment in close friends or relatives.
Recruitment of research subjects. No attempt was made to
obtain a random sample of Ontario society. We reasoned
that only highly motivated subjects would be willing to
complete this rather difficult questionnaire and that we could
not expect more than a very low compliance if we selected
subjects at random. Eighty volunteers (40 in Toronto and 40
in Kingston) each agreed to distribute and collect five copies
of the questionnaire among their acquaintances. The
Kingston recruiters were 40 members of the scientific and
non-medical staff of the Kingston Regional Cancer Centre,
and in Toronto 20 recruiters were volunteers from the
Canadian Cancer Society and 20 were paramedical staff
from the Princess Margaret Hospital. The recruiters were
asked to distribute their questionnaires to people who were
over the age of 20, who were not physicians and who were
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instructed not to discuss the questionnaire with the volun-
teers until after it had been returned completed. Volunteers
were told that the questionnaire concerned public attitudes
to cancer research and treatment and that the questionnaire
would take at least half an hour to complete. They were
asked not to accept the questionnaire unless they believed
they would find the time to complete it. The recruiters were
encouraged to try and get the questionnaires back within
two weeks and all those which were analysed were returned
within one month. The recruiters told each of their volun-
teers that the sealed package which they were given con-
tained a questionnaire and an inner sealed envelope which
must not be opened until the first section had been com-
pleted. Volunteers were asked to complete the questionnaire
alone and in private and not to discuss it with others until it
had been completed.
Data management and analysis. A dBase III Plus (Ashton-
Tate) file was written to accommodate the data, which were
primarily abstracted from the questionnaire on to an
abstraction sheet and subsequently entered into the computer
using a screen format identical to that of the abstraction
sheet. The information was then uploaded to the Queen's
University mainframe computer for analysis by Statistical
Analysis System (SAS) version 5 (SAS Institute Inc.). x2
contingency table analysis was used to study the significance
of simple differences in proportions and multifactor analysis
(logistic regression) was used to study the influence of
multiple variables on decisions regarding individuals' consent
to participate in clinical trials.
Results
Doctors' interpretation of expert surrogate data
Only 45 of the 79 doctors (57%) completed the second
questionnaire. Of these, 84% thought that the six trials
chosen in the first study were representative of ongoing work
in the field. Ninety-three per cent said that the views of their
colleagues would not alter their personal decisions regarding
their choice of management or their decision to participate
or not in the clinical trials. Sixty-nine per cent of our
respondents thought that new clinical trials should be sub-
mitted for evaluation by expert surrogates before they were
opened to patients.
Table I shows that when the majority of expert surrogates
consented to a given trial there was almost unanimous
agreement among doctors that the trial was acceptable for
patients. Even those doctors who did not personally consent
to participate agreed that these trials were acceptable. On the
other hand, where most doctors did not consent, the major-
ity of those who would personally refuse regarded the trial
as unacceptable but the majority of those who would
personally participate regarded the trial as acceptable for
patients.
Survey of lay people
Characteristics of the population surveyed. Three hundred
and forty-four of the 400 questionnaires (86%) were
returned appropriately completed. Two-thirds of the respon-
dents were women. Thirty-one per cent were 19-29 years old,
23% were 30-39, 18% were 40-49 and 28% were 50 or
older. One-half resided in Toronto, and one-half resided in
Kingston. (The responses of people from Toronto did not
differ from the responses of people from Kingston, so the
entire group of respondents is considered together.) Most
individuals were married (57%). Nearly one-half (47%) had
a university education, one-quarter (26%) had a college
education and one-quarter (27%) had either an elementary
or high-school education. The majority (79%) were born in
North America. Seventy-eight per cent were non-smokers.
Table II illustrates that the majority of respondents were in
good health and only a minority had experienced a major
illness in their lifetime. Most, however, were familiar with
cancer through the experiences of close friends or relatives.
Attitudes of surrogate patients to the surgical trial (LCSG-
821). Surrogate patients were asked if they would partici-
pate in the surgical trial outlined above (LCSG-821) and 343
answered this question. One hundred and seventy-three
(50.4%) consented and 170 (49.6%) refused. Reasons given
Table II Experience of illness
Experience %
Serious illness requiring hospitalisation 21.0
Chronic medical illness 14.0
Malignant disease 1.5
Close friend/relative with cancer 83.0
Close friend/relative who received radiotherapy for cancer 61.0
Close friend/relative who received chemotherapy for cancer 58.0
Close friend/relative who received surgery for cancer 68.0
Close friend/relative who died of cancer 68.0
Table III Reasons to participate or not to participate in the
surgery study
Reasons to participate
Perceived absence of risk 47.4%
Altruism 41.6%
Expectation of best possible care on study 15.6%
Preference for experimental treatment 12.7%
Trust in doctors 5.2%
Reasons not to participate
Preference for standard treatment 61.8%
Objection to randomisation 27.1%
Lack of information 14.1%
Preference for experimental treatment 7.1%
Preference for personalised treatment 6.5%
Often more than one answer was given.
Table I
Percentage of doctors who said
the trials should be stopped
in the resurvey
Percentage consent by Doctors who Doctors who
Study expert surrogates personally personally
codename in original survey All doctors consented refused
LSCG-821 64 5 4 8
EORTC-08824 57 0 0 0
LCSG-791 31 41 20 46
YALE-LUN-1 27 53 16 59
SWOG-8241 19 59 29 65
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for consent or for refusal are shown in Table III. The'most
common reason given for participating in this trial was the
view that it presented no risk but many also stated that they
would participate in order to help other people with cancer
in the future. A few believed that they would receive the best
possible care by participating in the clinical trial. The most
common reason given for refusing to participate was a
prefercnce for the standard trcatment. Only a small minority
expressed a preference for the experimental treatment. In
addition, a substantial number expressed a specific objection
to the process of randomisation in this setting. A few felt
that insufficient information about the trial had becn given
to allow them to participate.
After the surrogates had been informed of the doctors'
decisions in the same circumstances, they were asked again if
they would consent to participate in this clinical study and
49.6% now consented and 50.4% refused. Fifteen people had
changed their decision from yes to no and 13 from no to yes.
Figure 1 shows the effect of the subject's age on the
frequency of consent to the trial, both before and after being
informed of the decisions of the doctors. People under 30
and over 60 were willing to consent to the trial more
frequently than the intermediate age groups (P<0.05). Parti-
cipation was not influenced by sex, education, marital status,
country of birth, experience with cancer or smoking status.
Tablc IV shows the way in which respondents' decisions
were influenced by the doctors' opinions according to the
type of information which the subject had received. There
was a significantly higher frequency of transitions from yes
to no in the subgroup which had received the information
about the doctors' decisions in the negative frame accom-
panied by a statemcnt of their reasons for refusing
(P<0.05). The presentation of the information in the nega-
tive frame alone without giving the doctors' reasons for
refusal did not produce this effect nor did the addition of the
reasons when the doctors' views were presented in the mixed
frame (for an cxplanation of positivc, negative and mixed
frame see Methods).
Attitudles of surr-ogate patients to the chemotherapv trial
(SWOG-8241). Surrogate patients were asked if they would
participate in the chemotherapy trial outlined above and 341
answered this question. One hundred and sixty-four (48.1%)
consented and 177 (51.9%) refused. Reasons given for
consent or refusal are shown in Table V. The most common
reason for consent to this trial was the belief that participa-
tion would help others in the same situation in the future. A
large proportion of patients also believed that they would
receive the best possible care by participating in the study. In
this situation, only a few patients stated that they could see
no risk in participation. The most common reason for
refusing to participate was concern about the toxicity of the
treatment or the perceived poor quality of life associated
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Figure 1 The effect of' age on the frequency of consent by lay
pcople to participate in the surgical trial (LCSG-821), before and
after disclosure of the doctors' decisions. tilled columns, before;
hatched columiins, alf'ter.
Table IV The frequency of transitions in the surgical
trial (LCSG-821) as a function of the way in which the
doctors' decisions were communicated to the respondents
Fr-am1e YN NY YY NN Totl
Positive 2 5 33 27 67
Negative 0 2 31 36 69
Mixed 1 1 32 33 67
Negative + reasons 9 2 23 33 67
Mixed + reasons 3 3 35 27 68
Total 15 13 154 156 338
The framing variables introduced into the questionnaire
are described in detail in Methods. YN =respondents who
originally consented to participate in the trial and later re-
fused when informed of the doctors' decisions; NY=
those who originally refused to participate in the trial and
later consented when informed of the doctors' decisions;
YY=those who consented both before and after being
informed of the doctors' decisions; NN= those who
refused both before aInd after being informed of the
doctors' decisions.
Table V Reasons to participate or not in the chemotherapy study
Reasons10 palrtiipate
Altruism
Expectation of best possible care on study
Perceived absence of risk
Trust in doctors
Reasons niot to palitipate
Perception that treatment would result in poor quality
of life
Perception that chemotherapy is not effective
Preferenice for standard treattment
Lack of information
Objection to randomisation
Perception that the trial was useless
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61.6'V
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with the forms of treatment involved in the study. A large
proportion also expressed the concern that the chemotherapy
was not likely to help them very much. A few expressed a
preference for standard treatment and some felt that insuf-
ficient information had been presented to permit them to
consent. A smaller proportion objected to randomisation in
this context than in the context of the previous study.
After the surrogates had been told of the doctors'
decisions in the same circumstances, they were asked again if
they would consent to this study and 30.1% now consented
and 69.9% refused. Sixty-one individuals changed their mind
from yes to no and one from no to yes and this difference is
statistically significant (P<0.0001).
Figure 2 shows the effect of the age of the subjects on the
frequency of consent to the chemotherapy trial. As in the
a)
a)
_ Before
After
4 2 35
20-
0-
20- 29 30 39 40 49 50 59 60
Age grouping
Figure 2 The effect of' age oni the frequency of consent by lay
people to participate in the chemotherapy trial (SWOG-8241),
before Cand after disclosure of the doctors' decisions. Filled
columns, before; hatched columns, after.392 W.J. MACKILLOP et al.
surgery study, patients over the age of 60 and under the age
of 30 were more likely to consent to the trial before receiving
any information about the doctors' decisions, but this was
not significant. Participation was not influenced by sex,
education, marital status, country of birth, experience with
cancer or smoking status. Young people, however, were
more likely to change their minds when informed of the
doctors' decisions than were the elderly (P<0.05).
There was no association between consent to the surgery
trial and consent to the chemotherapy trial. Forty-six per
cent of lay people who consented to the surgery trial also
consented to the chemotherapy trial, and 50% of lay people
who did not consent to the surgery trial consented to the
chemotherapy trial.
Table VI shows the frequency of transitions in response to
the doctors' decisions as a function of the type of question-
naire the subject had received. In this situation, neither the
manner in which the doctors' views were presented nor
inclusion or omission of the reasons for their decisions,
influenced the behaviour of the surrogate patients. In each
case approximately 40% of those who had initially consented
changed their minds.
Attitudes of lay people to expert surrogate process. Eighty-
three per cent of lay people stated that they would wish to
know the views of expert surrogates before deciding whether
to consent to a clinical trial if they had cancer and 79%
thouLght that any cancer patient should be given this type of
information before being asked to consent to participate in
. clilnical iml. Most ol our 0 nhjects (74%) believed that cancer
specialists should be asked if they would be willing to
Table VI t rcquency of transitions in the chemotherapy
trial (SWOG-8241) as a function of the way in which the
doctors' decisions were communicated to the respondents
Frame YN NY YY NN Total
Positive 13 0 19 33 65
Negative 11 0 19 39 69
Mixed 13 1 21 31 66
Negative+reasons 11 0 18 39 68
Mixed+reasons 13 0 24 32 69
Total 61 1 101 174 337
The framing variables introduced into the questionnaire
are described in detail in Methods. YN=respondents who
originally consented to participate in the trial and later
refused when informed of the doctors' decisions;
NY=those who originally refused to participate in the
trial and later consented when informed of the doctors'
decisions; YY=those who consented both before and after
being informed of the doctors' decisions; NN=those who
refused both before and after being informed of the
doctors' decisions.
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Figure 3 The proportion of lay people who regard a clinical
trial as acceptable as a function of the proportion of experts who
would be prepared to participate in it.
participate in clinical trials before these were opened to
patients. Those who thought that it was useful to ask cancer
specialists this question were also asked what proportion of
doctors should be required to consent in order that a trial be
considered ethically acceptable. Their answers to this
question are expressed in the form of a cumulative frequency
distribution in Figure 3.
Discussion
We have shown that lay people were unable to discern any
difference in acceptability between two clinical trials which
appeared markedly different to experts in the field. Although
the individuals surveyed do not represent a cross-section of
society, it is improbable that the average lay person would
prove to be more discriminating than the members of this
unusually well educated group. The surrogate patients also
had the opportunity to reflect on the possible costs and
benefits of treatment without the emotional stress of a real
illness (Fost, 1975). It is, therefore, improbable that the
average cancer patient would, in reality, exercise better
judgement than these surrogate patients. Modern medical
ethics emphasise patients' rights to make their own decisions
about their medical care (Sider & Clements, 1985) but lay
people appear to be ill-equipped to judge for themselves the
risks and benefits of participation in a clinical trial. Some
form of review process is, therefore, essential to ensure that
patients are not asked to participate in clinical experiments
with unacceptable risk/benefit ratios.
The issue of what constitutes an ethical clinical experiment
is currently decided by the experts who design clinical trials,
who may not be disinterested parties, and by disinterested
reviewers on an ethics committee, who may not be experts.
We believe that this system of evaluation is flawed by the
separation of the two key elements of expertise and impartia-
lity and that additional strategies must be developed to assist
in judging the ethical acceptability of clinical research
protocols.
The majority of doctors and lay people surveyed in this
investigation were in favour of the use of expert surrogates
to evaluate new clinical trials before they were opened to
patients, although we acknowledge that the sample of pro-
fessional opinion was less than optimal. There was also a
reasonable degree of consensus on how the results of an
expert surrogate evaluation might be interpreted. Lay people,
on average, wanted the consent of 64% of experts before a
trial was opened to patients. Regardless of their personal
treatment preference, doctors were almost unanimous that
trials to which more than 50% of expert surrogates con-
sented were acceptable. Thus, trials to which two-thirds of
expert surrogates consent appear ethically acceptable to the
majority of lay people and physicians.
We have previously suggested that, apart from the propor-
tion of doctors consenting, the reasons given by those who
refuse should also be carefully considered. If, for example,
some doctors refused to participate in a two-arm randomised
trial because they had a preference for one treatment option
offered in the trial while others refused to participate
because they preferred the other option, then their refusal
would merely confirm the existence of the controversy which
the trial was designed to address. A low overall consent by
expert surrogates in this situation could be regarded as a
demonstration of the 'clinical equipoise' which Freedman
(1987) regards as the hallmark of an ethical randomised trial.
However, this concept is not relevant to the two clinical
trials which were evaluated here by lay people since we
found no evidence of equipoise. In one trial all those experts
who refused to participate rejected all arms of the study
(SWOG-8241) and in the other all those who refused rejected
only the experimental arm (LCSG-821) (Mackillop et al., 1986).
The problem of applying the golden rule to medical
decision making is that we run the risk of inflicting our
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personal system of values on our patients. We cannot
assume that our choice of treatment will automatically be
correct for a patient, particularly in a palliative setting where
optimal treatment may vary according to patients' willing-
ness to take risks and the way in which they weigh quality
versus quantity of life. However, it does appear to us
reasonable for the medical profession to apply the rule
collectively, particularly if it is framed in its negative form,
i.e. that a doctor should not offer a patient treatment which
the majority of experts in the field would refuse if they were
in the patient's position (Mackillop et al., 1988a).
The majority of lay people would wish to know, for
themselves, whether experts in the field would consent to
participate in a clinical trial before they would agree to
participate. It has also been demonstrated that the views of
expert surrogates may lead potential research subjects to
alter their decisions. Thus, the data resulting from an expert
surrogate survey might be regarded as material information
which should be given to patients who are asked to consent
to participate in a clinical trial although it was not our initial
intention that the information should be used in this way.
The opinions of lay people have previously been studied in
the attempt to determine individual patient preferences for
management in a number of situations (McNeil et al., 1982;
O'Connor et al., 1985). One important finding was that the
manner in which information is presented to lay people has
an effect on the way that they interpret it. We have also
shown that the manner in which data are presented to
surrogate patients may influence their response, particularly
when the collective views of the physicians are not uniform.
When, however, a large majority of doctors is in favour of
one course of action, the manner in which their opinions are
presented to surrogate patients has no effect on the way in
which they influence surrogate patients' decisions.
Clinical research is undoubtedly an important part of
oncology today. Clinical trials have already resolved many
long-standing controversies and now ensure that new forms
of therapy are evaluated fairly and cautiously before they
become accepted into routine practice. It is vitally important,
therefore, that the medical community should set high and
consistent standards for the practice of clinical research. In
the long-term, the number of patients available and willing
to participate in clinical experiments will depend on the
credibility of the research community in the eyes of the
public and of the medical profession as a whole. Further
attempts to refine the process of reviewing ethical standards
in clinical research are not merely important to protect the
interests of today's patients but also to protect the integrity
of a process which promises great benefits for future gene-
rations of patients.
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Appendices
Appendix I
SITUATION A
You are found to have lung cancer:
An X-ray taken of your chest during a routine check-up shows an abnormality in your right lung. You are admitted to
hospital for further investigations. A chest specialist passes a tube down your throat and finds a small tumour in your right
lung. Further testing confirms a diagnosis of lung cancer. You have no symptoms, and feel fine.
Your doctor tells you about possible treatments:
Your doctor explains to you that the right lung has three sections, called lobes, and that your cancer is only in the upper (top)
lobe. Surgery is the best method of treating this kind of early lung cancer, and all of the cancer can often be removed by
surgery. The usual treatment is to cut out the entire upper lobe. Some doctors think that it should be possible to cure this kind
of tumour with a smaller operation, by cutting out a segment of the upper lobe containing the cancer. It is not known which is
the better treatment.
You are asked to participate in a study:
Your doctor asks you if you would be willing to participate in the study that the doctors in the hospital are involved with to
see whether it is better to remove the entire lobe or only a segment of it. All of the patients in the study have lung cancer that
can be removed by surgery, like yourself. The intent of the surgery is to cure you of the cancer.
Participation in the study is voluntary. Your doctor tells you that you have every right not to take part. You are assured
that if you decide not to take part, you will be treated with surgery in the usual way (complete removal of upper lobe). If you
agree to participate, there is an equal chance that you would either have the entire upper lobe of your right lung removed by
surgery, or have a segment of it removed by surgery. The treatment that you receive would be decided randomly by a
computer. (This means the treatment is decided by chance, just like flipping a coin.) Your doctor does not know in advance
which kind of treatment you would receive.
You are told about possible side effects:
Your doctor tells you that there is always a slight risk associated with surgery, but the chances of severe complications, or
death, are small. There is no known difference between the two operations in terms of risk. Most patients are in the hospital
for two or three weeks, and have some pain around their incisions. After spending a month or so recuperating at home, you
should feel fine, and only need to return to the hospital for regular checkups after that.394 W.J. MACKILLOP et al.
Appendix 2
SITUATION B
You are found to have lung cancer:
You have generally been feeling unwell for some time, and have lost 20 pounds in weight. You begin to experience a constant
pain in your lower back, and make an appointment to see your doctor. A chest X-ray shows an abnormality in your right
lung that is suspected of being lung cancer. You are admitted to hospital for further investigations. A chest specialist takes a
sample of the tumour and you are told the next day that you have lung cancer. Further testing is carried out over the next few
days. Your doctor then tells you that the cancer has spread from the lung to the bones in your lower back and this is why you
have pain in that area.
Your doctor tells you about possible treatments:
You are told that because the cancer has spread, surgery would be of no use. However, the cancer may be treated by
chemotherapy or radiotherapy. There are many different combinations of drugs that could be used. It is not known which is
the best combination.
You are asked to participate in a study:
Your doctor asks you if you would be willing to participate in the study that the doctors in the hospital are conducting to see
which of five possible combinations of drugs is best, in treating a cancer like yours. All of the patients in the study have lung
cancer that cannot be removed by surgery, and symptoms like the back pain and weight loss that you have experienced. The
intent of the chemotherapy is to shrink the tumour or at least to slow down its growth, but there is no hope of cure.
Participation in the study is voluntary. Your doctor tells you that you have every right not to take part. You are assured
that if you decide not to take part, you would be given radiation treatment to the painful areas, and painkillers. If you agree
to participate, there is an equal chance that you would receive one of five different kinds of combination chemotherapy as
treatment for your lung cancer. Each combination involves two or three drugs. The treatment that you receive would be
decided randomly by a computer. (This means the treatment is decided by chance, just like flipping a coin.) Your doctor does
not know in advance which kind of treatment you would receive.
You are told about possible side effects:
Your doctor tells you that the drugs will be given to you through a tube put into a vein in your arm. The treatment is given
every three weeks. Any one of the drug combinations will make you feel sick to your stomach and cause you to vomit for a
day or two, and you will also lose your hair. During the course of the treatment, it is possible that you may also experience
other side effects such as an increased risk of infection, bruising or bleeding, fever, bladder irritation, numbness and tingling in
hands and feet, diarrhoea, and kidney damage. The doctors will make every effort to avoid these more serious complications.
Appendix 3
SITUATION A
This is what the Ontario cancer specialists said when we asked them if they would consent to be treated as patients in the first
study, in Situation A:
64% of the doctors would consent to participate in the study of complete versus partial surgical removal of the upper lobe.
36% of the doctors refused to participate in the study of complete versus partial surgical removal of the upper lobe.
Most of the doctors who refused to participate did so because they had a definite preference for one of the two treatments
offered by the study.
33% of the doctors refused to participate because they preferred complete surgical removal of the upper lobe. All of them
said that they thought that the smaller operation might be inadequate.
None of the doctors preferred the other form of treatment in which only a segment of the lung is removed.
3% of the doctors would not participate because they wanted additional chemotherapy or radiation treatment, which were
not included in the study.
Appendix 4
SITUATION B
This is what the Ontario cancer specialists said when we asked them if they would consent to be treated as patients in the
second study, in Situation B:
19% of doctors would consent to participate in the study of the five types of combination chemotherapy.
81% of doctors refused to participate in the study of the five types of combination chemotherapy.
Most of the doctors refused to participate because they did not want any form of chemotherapy in this situation. Of those
doctors who would not participate, 70% thought that chemotherapy would be ineffective and 60% thought that chemotherapy
would be too toxic. 17% of doctors wanted radiation as additional treatment.CLINICAL TRIALS IN CANCER 395
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